Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Integra Lifesciences Holdings (IART) Invested Capital (2016 - 2026)

Integra Lifesciences Holdings' Invested Capital history spans 17 years, with the latest figure at $1.8 billion for Q4 2025.

  • On a quarterly basis, Invested Capital fell 23.23% to $1.8 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.8 billion, a 23.23% decrease, with the full-year FY2025 number at $1.8 billion, down 23.23% from a year prior.
  • Invested Capital hit $1.8 billion in Q4 2025 for Integra Lifesciences Holdings, roughly flat from $1.8 billion in the prior quarter.
  • Over the last five years, Invested Capital for IART hit a ceiling of $2.6 billion in Q4 2022 and a floor of $1.8 billion in Q4 2025.
  • Historically, Invested Capital has averaged $2.3 billion across 5 years, with a median of $2.4 billion in 2021.
  • Biggest five-year swings in Invested Capital: increased 9.64% in 2021 and later decreased 23.23% in 2025.
  • Tracing IART's Invested Capital over 5 years: stood at $2.5 billion in 2021, then rose by 2.01% to $2.6 billion in 2022, then decreased by 8.39% to $2.4 billion in 2023, then fell by 2.42% to $2.3 billion in 2024, then decreased by 23.23% to $1.8 billion in 2025.
  • Business Quant data shows Invested Capital for IART at $1.8 billion in Q4 2025, $1.8 billion in Q3 2025, and $1.8 billion in Q2 2025.